Friday, July 10, 2026

pharma · Female Infertility · Breast Feeding

Abbott Pathology

Abbott Australasia Pty is a pharma organization headquartered in ROME, AU. Primary therapeutic focus areas include Female Infertility, Breast Feeding, Children, Sarcoma, Kaposi, Diabetic Nephropathy. NovaPharmaNews links

Mile End, AU HQ
2001 Founded
41 Employees
TGA registrant Type
Company details
Status
Public
HQ
Mile End, AU
Founded
2001
Employees
41
Programs
6
Drugs
9
Patents
0

Quick answer

Abbott Australasia Pty is a pharma organization headquartered in ROME, AU. Primary therapeutic focus areas include Female Infertility, Breast Feeding, Children, Sarcoma, Kaposi, Diabetic Nephropathy. NovaPharmaNews links 6 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), phase 2 (2).

Company snapshot

Abbott Pathology is a South Australian Pathology Laboratory providing high quality, diagnostic Pathology Services to medical specialists, general practitioners, commercial and Government organisations in South Australia. Our vision is “to become the preferred provider of medical diagnostic information in SA by providing a strong customer focus and by creating a stimulating work environment for emp

  • 6 active pipeline program(s) linked via ClinicalTrials.gov.
  • 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Abbott Pathology. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Abbott Pathology.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 6 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Abbott Pathology.

  1. Clinical update

    Zemplar (paricalcitol ) capsules — Phase 2

  2. Clinical update

    nutritional supplement — Phase 3

  3. Clinical update

    Dydrogesterone 30 mg — Phase 3

  4. Clinical update

    ZoMaxx™ Drug-Eluting Coronary Stent System — Phase 3

  5. Clinical update

    Ritonavir — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Abbott Pathology?

    Abbott Australasia Pty is a pharma organization headquartered in ROME, AU. Primary therapeutic focus areas include Female Infertility, Breast Feeding, Children, Sarcoma, Kaposi, Diabetic Nephropathy. NovaPharmaNews links 6 clinical program(s), 3 drug profile(s), and 0 patent reco

  • Is Abbott Pathology publicly traded?

    Abbott Pathology appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Abbott Pathology develop or market?

    We link 9 drug profile(s) where Abbott Pathology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/abbott-s-r-l#company-drugs.

  • What are the latest developments for Abbott Pathology?

    In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Abbott Pathology focus on?

    Abbott Pathology focuses on Female Infertility, Breast Feeding, Children based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
12
Infectious Disease
1